Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Sep 6;4(1):FSO230.
doi: 10.4155/fsoa-2017-0069. eCollection 2018 Jan.

Advances in nanomedicine drug delivery applications for HIV therapy

Paul Curley  1   1 , Neill J Liptrott  1   2   1   2 , Andrew Owen  1   2   1   2
Affiliations
Editorial

Advances in nanomedicine drug delivery applications for HIV therapy

Paul Curley et al. Future Sci OA. .
No abstract available

Keywords: HIV; biocompatibility; long-acting antiretroviral; nanomedicine.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure A Owen is a coinventor of patents relating to the application of nanotechnology to HIV drug delivery and is cofounder of a University of Liverpool startup company, Tandem Nano Ltd. A Owen has also received funding from Merck, Janssen, ViiV Healthcare, AstraZeneca and Pfizer. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Figures

<b>Figure 1.</b>
Figure 1.. Shows some of the limitations of current antiretroviral therapy and opportunities to address these limitations via nanomedicine.
(1) Conventional oral nanomedicine is effective at achieving therapeutic concentrations of antiretrovirals and maintaining suppression of viral replication. However, application of oral nanomedicine offers potential benefits such as dose reduction, reduced toxicity and improved bioavailability. (2) Subtherapeutic concentrations of antiretrovirals in sanctuary sites allow continued viral replication in key anatomical and cellular regions despite viral suppression in the plasma. Targeted nanomedicines offer the opportunity to deliver therapeutic concentrations of antiretrovirals to sanctuary sites. (3) Poor patient adherence may produce subtherapeutic concentrations of antiretrovirals which may lead to viral rebound. Application of long-acting nanomedicines may mitigate the risk effects of poor patient compliance.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Rosenbloom DI, Hill AL, Rabi SA, Siliciano RF, Nowak MA. Antiretroviral dynamics determines HIV evolution and predicts therapy outcome. Nat. Med. 2012;18(9):1378–1385. - PMC - PubMed
    1. Owen A, Rannard S. Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: insights for applications in HIV therapy. Adv. Drug Deliv. Rev. 2016;103:144–156. - PMC - PubMed
    1. Poveda E, Tabernilla A. New insights into HIV-1 persistence in sanctuary sites during antiretroviral therapy. AIDS Rev. 2016;18(1):55. - PubMed
    1. Cory TJ, Schacker TW, Stevenson M, Fletcher CV. Overcoming pharmacologic sanctuaries. Curr. Opin. HIV AIDS. 2013;8(3):190–195. - PMC - PubMed
    1. Tatham LM, Rannard SP, Owen A. Nanoformulation strategies for the enhanced oral bioavailability of antiretroviral therapeutics. Ther. Deliv. 2015;6(4):469–490. - PubMed

Publication types

LinkOut - more resources